In our analysis of relapsed and refractory MM patients, either early (ERMM, 1–3 prior lines of treatment) or late (LRMM, >3 prior lines), we observed an upregulation of PDIA1 expression, suggesting that the gain of ER function may contribute to the refractory state that results in poor survival. Here, P4HB is linked to Miyoshi myopathy.